Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5c783aadc1-trace').style.display = (document.getElementById('cakeErr67f5c783aadc1-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f5c783aadc1-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5c783aadc1-code').style.display = (document.getElementById('cakeErr67f5c783aadc1-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5c783aadc1-context').style.display = (document.getElementById('cakeErr67f5c783aadc1-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f5c783aadc1-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f5c783aadc1-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20166,
		&#039;title&#039; =&gt; &#039;EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Economic Times
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, the Canadian Supreme Court refused to grant patent to Pfizer&#039;s Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
 &amp;quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&amp;quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
Last year, Argentina amended its patent act to incorporate a law that said &amp;quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&amp;quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &amp;quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&amp;quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&amp;quot; he added. India&#039;s Supreme Court on Monday declined to grant patent protection to Novartis&#039; blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &amp;quot;evergreening&amp;quot; or trivial innovations in an effort to get patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The decision by India&#039;s SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&amp;quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
She added that IP Australia&#039;s draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 4 April, 2013, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/eu-australia-canada-may-follow-indias-patent-law/articleshow/19369085.cm&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20307,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20166,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic drugs,medicines,patents,Cancer,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Economic Times



MUMBAI: India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Economic Times&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, the Canadian Supreme Court refused to grant patent to Pfizer&#039;s Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt; &amp;quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&amp;quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;Last year, Argentina amended its patent act to incorporate a law that said &amp;quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&amp;quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &amp;quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&amp;quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&amp;quot; he added. India&#039;s Supreme Court on Monday declined to grant patent protection to Novartis&#039; blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &amp;quot;evergreening&amp;quot; or trivial innovations in an effort to get patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The decision by India&#039;s SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&amp;quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;She added that IP Australia&#039;s draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20166,
	&#039;title&#039; =&gt; &#039;EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Economic Times
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, the Canadian Supreme Court refused to grant patent to Pfizer&#039;s Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
 &amp;quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&amp;quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
Last year, Argentina amended its patent act to incorporate a law that said &amp;quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&amp;quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &amp;quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&amp;quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&amp;quot; he added. India&#039;s Supreme Court on Monday declined to grant patent protection to Novartis&#039; blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &amp;quot;evergreening&amp;quot; or trivial innovations in an effort to get patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The decision by India&#039;s SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&amp;quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
She added that IP Australia&#039;s draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 4 April, 2013, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/eu-australia-canada-may-follow-indias-patent-law/articleshow/19369085.cm&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20307,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20166
$metaTitle = &#039;LATEST NEWS UPDATES | EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal&#039;
$metaKeywords = &#039;generic drugs,medicines,patents,Cancer,Health&#039;
$metaDesc = &#039;
-The Economic Times



MUMBAI: India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Economic Times&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, the Canadian Supreme Court refused to grant patent to Pfizer&#039;s Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt; &amp;quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&amp;quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;Last year, Argentina amended its patent act to incorporate a law that said &amp;quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&amp;quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &amp;quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&amp;quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&amp;quot; he added. India&#039;s Supreme Court on Monday declined to grant patent protection to Novartis&#039; blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &amp;quot;evergreening&amp;quot; or trivial innovations in an effort to get patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The decision by India&#039;s SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&amp;quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;She added that IP Australia&#039;s draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal | Im4change.org</title>
    <meta name="description" content="
-The Economic Times



MUMBAI: India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Economic Times</div><p align="justify"><br /><em>MUMBAI: </em>India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.</p><p align="justify">A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.</p><p align="justify">Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.</p><p align="justify">Last year, the Canadian Supreme Court refused to grant patent to Pfizer's Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.</p><p align="justify"> &quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.</p><p align="justify"><br />Last year, Argentina amended its patent act to incorporate a law that said &quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.</p><p align="justify">&quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&quot; he added. India's Supreme Court on Monday declined to grant patent protection to Novartis' blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &quot;evergreening&quot; or trivial innovations in an effort to get patent protection.</p><p align="justify">&quot;The decision by India's SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.</p><p align="justify">She added that IP Australia's draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5c783aadc1-trace').style.display = (document.getElementById('cakeErr67f5c783aadc1-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f5c783aadc1-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5c783aadc1-code').style.display = (document.getElementById('cakeErr67f5c783aadc1-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5c783aadc1-context').style.display = (document.getElementById('cakeErr67f5c783aadc1-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f5c783aadc1-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f5c783aadc1-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20166,
		&#039;title&#039; =&gt; &#039;EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Economic Times
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, the Canadian Supreme Court refused to grant patent to Pfizer&#039;s Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
 &amp;quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&amp;quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
Last year, Argentina amended its patent act to incorporate a law that said &amp;quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&amp;quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &amp;quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&amp;quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&amp;quot; he added. India&#039;s Supreme Court on Monday declined to grant patent protection to Novartis&#039; blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &amp;quot;evergreening&amp;quot; or trivial innovations in an effort to get patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The decision by India&#039;s SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&amp;quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
She added that IP Australia&#039;s draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 4 April, 2013, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/eu-australia-canada-may-follow-indias-patent-law/articleshow/19369085.cm&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20307,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20166,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic drugs,medicines,patents,Cancer,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Economic Times



MUMBAI: India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Economic Times&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, the Canadian Supreme Court refused to grant patent to Pfizer&#039;s Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt; &amp;quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&amp;quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;Last year, Argentina amended its patent act to incorporate a law that said &amp;quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&amp;quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &amp;quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&amp;quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&amp;quot; he added. India&#039;s Supreme Court on Monday declined to grant patent protection to Novartis&#039; blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &amp;quot;evergreening&amp;quot; or trivial innovations in an effort to get patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The decision by India&#039;s SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&amp;quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;She added that IP Australia&#039;s draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20166,
	&#039;title&#039; =&gt; &#039;EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Economic Times
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, the Canadian Supreme Court refused to grant patent to Pfizer&#039;s Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
 &amp;quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&amp;quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
Last year, Argentina amended its patent act to incorporate a law that said &amp;quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&amp;quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &amp;quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&amp;quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&amp;quot; he added. India&#039;s Supreme Court on Monday declined to grant patent protection to Novartis&#039; blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &amp;quot;evergreening&amp;quot; or trivial innovations in an effort to get patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The decision by India&#039;s SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&amp;quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
She added that IP Australia&#039;s draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 4 April, 2013, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/eu-australia-canada-may-follow-indias-patent-law/articleshow/19369085.cm&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20307,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20166
$metaTitle = &#039;LATEST NEWS UPDATES | EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal&#039;
$metaKeywords = &#039;generic drugs,medicines,patents,Cancer,Health&#039;
$metaDesc = &#039;
-The Economic Times



MUMBAI: India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Economic Times&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, the Canadian Supreme Court refused to grant patent to Pfizer&#039;s Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt; &amp;quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&amp;quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;Last year, Argentina amended its patent act to incorporate a law that said &amp;quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&amp;quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &amp;quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&amp;quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&amp;quot; he added. India&#039;s Supreme Court on Monday declined to grant patent protection to Novartis&#039; blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &amp;quot;evergreening&amp;quot; or trivial innovations in an effort to get patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The decision by India&#039;s SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&amp;quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;She added that IP Australia&#039;s draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal | Im4change.org</title>
    <meta name="description" content="
-The Economic Times



MUMBAI: India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Economic Times</div><p align="justify"><br /><em>MUMBAI: </em>India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.</p><p align="justify">A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.</p><p align="justify">Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.</p><p align="justify">Last year, the Canadian Supreme Court refused to grant patent to Pfizer's Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.</p><p align="justify"> &quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.</p><p align="justify"><br />Last year, Argentina amended its patent act to incorporate a law that said &quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.</p><p align="justify">&quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&quot; he added. India's Supreme Court on Monday declined to grant patent protection to Novartis' blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &quot;evergreening&quot; or trivial innovations in an effort to get patent protection.</p><p align="justify">&quot;The decision by India's SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.</p><p align="justify">She added that IP Australia's draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5c783aadc1-trace').style.display = (document.getElementById('cakeErr67f5c783aadc1-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f5c783aadc1-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5c783aadc1-code').style.display = (document.getElementById('cakeErr67f5c783aadc1-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5c783aadc1-context').style.display = (document.getElementById('cakeErr67f5c783aadc1-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f5c783aadc1-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f5c783aadc1-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20166,
		&#039;title&#039; =&gt; &#039;EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Economic Times
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, the Canadian Supreme Court refused to grant patent to Pfizer&#039;s Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
 &amp;quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&amp;quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
Last year, Argentina amended its patent act to incorporate a law that said &amp;quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&amp;quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &amp;quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&amp;quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&amp;quot; he added. India&#039;s Supreme Court on Monday declined to grant patent protection to Novartis&#039; blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &amp;quot;evergreening&amp;quot; or trivial innovations in an effort to get patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The decision by India&#039;s SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&amp;quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
She added that IP Australia&#039;s draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 4 April, 2013, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/eu-australia-canada-may-follow-indias-patent-law/articleshow/19369085.cm&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20307,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20166,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic drugs,medicines,patents,Cancer,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Economic Times



MUMBAI: India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Economic Times&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, the Canadian Supreme Court refused to grant patent to Pfizer&#039;s Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt; &amp;quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&amp;quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;Last year, Argentina amended its patent act to incorporate a law that said &amp;quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&amp;quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &amp;quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&amp;quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&amp;quot; he added. India&#039;s Supreme Court on Monday declined to grant patent protection to Novartis&#039; blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &amp;quot;evergreening&amp;quot; or trivial innovations in an effort to get patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The decision by India&#039;s SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&amp;quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;She added that IP Australia&#039;s draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20166,
	&#039;title&#039; =&gt; &#039;EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Economic Times
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, the Canadian Supreme Court refused to grant patent to Pfizer&#039;s Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
 &amp;quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&amp;quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
Last year, Argentina amended its patent act to incorporate a law that said &amp;quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&amp;quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &amp;quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&amp;quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&amp;quot; he added. India&#039;s Supreme Court on Monday declined to grant patent protection to Novartis&#039; blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &amp;quot;evergreening&amp;quot; or trivial innovations in an effort to get patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The decision by India&#039;s SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&amp;quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
She added that IP Australia&#039;s draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 4 April, 2013, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/eu-australia-canada-may-follow-indias-patent-law/articleshow/19369085.cm&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20307,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20166
$metaTitle = &#039;LATEST NEWS UPDATES | EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal&#039;
$metaKeywords = &#039;generic drugs,medicines,patents,Cancer,Health&#039;
$metaDesc = &#039;
-The Economic Times



MUMBAI: India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Economic Times&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;India&#039;s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, the Canadian Supreme Court refused to grant patent to Pfizer&#039;s Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt; &amp;quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&amp;quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;Last year, Argentina amended its patent act to incorporate a law that said &amp;quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&amp;quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &amp;quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&amp;quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&amp;quot; he added. India&#039;s Supreme Court on Monday declined to grant patent protection to Novartis&#039; blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &amp;quot;evergreening&amp;quot; or trivial innovations in an effort to get patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The decision by India&#039;s SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&amp;quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;She added that IP Australia&#039;s draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal | Im4change.org</title>
    <meta name="description" content="
-The Economic Times



MUMBAI: India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Economic Times</div><p align="justify"><br /><em>MUMBAI: </em>India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.</p><p align="justify">A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.</p><p align="justify">Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.</p><p align="justify">Last year, the Canadian Supreme Court refused to grant patent to Pfizer's Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.</p><p align="justify"> &quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.</p><p align="justify"><br />Last year, Argentina amended its patent act to incorporate a law that said &quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.</p><p align="justify">&quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&quot; he added. India's Supreme Court on Monday declined to grant patent protection to Novartis' blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &quot;evergreening&quot; or trivial innovations in an effort to get patent protection.</p><p align="justify">&quot;The decision by India's SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.</p><p align="justify">She added that IP Australia's draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 20166,
		'title' => 'EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal',
		'subheading' => '',
		'description' => '<div align="justify">
-The Economic Times
</div>
<p align="justify">
<br />
<em>MUMBAI: </em>India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.
</p>
<p align="justify">
A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.
</p>
<p align="justify">
Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.
</p>
<p align="justify">
Last year, the Canadian Supreme Court refused to grant patent to Pfizer's Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.
</p>
<p align="justify">
 &quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.
</p>
<p align="justify">
<br />
Last year, Argentina amended its patent act to incorporate a law that said &quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.
</p>
<p align="justify">
&quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&quot; he added. India's Supreme Court on Monday declined to grant patent protection to Novartis' blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &quot;evergreening&quot; or trivial innovations in an effort to get patent protection.
</p>
<p align="justify">
&quot;The decision by India's SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.
</p>
<p align="justify">
She added that IP Australia's draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.
</p>',
		'credit_writer' => 'The Economic Times, 4 April, 2013, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/eu-australia-canada-may-follow-indias-patent-law/articleshow/19369085.cm',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 20307,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 20166,
	'metaTitle' => 'LATEST NEWS UPDATES | EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal',
	'metaKeywords' => 'generic drugs,medicines,patents,Cancer,Health',
	'metaDesc' => '
-The Economic Times



MUMBAI: India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top...',
	'disp' => '<div align="justify">-The Economic Times</div><p align="justify"><br /><em>MUMBAI: </em>India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.</p><p align="justify">A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.</p><p align="justify">Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.</p><p align="justify">Last year, the Canadian Supreme Court refused to grant patent to Pfizer's Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.</p><p align="justify"> &quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.</p><p align="justify"><br />Last year, Argentina amended its patent act to incorporate a law that said &quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.</p><p align="justify">&quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&quot; he added. India's Supreme Court on Monday declined to grant patent protection to Novartis' blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &quot;evergreening&quot; or trivial innovations in an effort to get patent protection.</p><p align="justify">&quot;The decision by India's SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.</p><p align="justify">She added that IP Australia's draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 20166,
	'title' => 'EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal',
	'subheading' => '',
	'description' => '<div align="justify">
-The Economic Times
</div>
<p align="justify">
<br />
<em>MUMBAI: </em>India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.
</p>
<p align="justify">
A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.
</p>
<p align="justify">
Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.
</p>
<p align="justify">
Last year, the Canadian Supreme Court refused to grant patent to Pfizer's Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.
</p>
<p align="justify">
 &quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.
</p>
<p align="justify">
<br />
Last year, Argentina amended its patent act to incorporate a law that said &quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.
</p>
<p align="justify">
&quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&quot; he added. India's Supreme Court on Monday declined to grant patent protection to Novartis' blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &quot;evergreening&quot; or trivial innovations in an effort to get patent protection.
</p>
<p align="justify">
&quot;The decision by India's SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.
</p>
<p align="justify">
She added that IP Australia's draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.
</p>',
	'credit_writer' => 'The Economic Times, 4 April, 2013, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/eu-australia-canada-may-follow-indias-patent-law/articleshow/19369085.cm',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'eu-australia-canada-may-follow-indias-patent-law-divya-rajagopal-20307',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 20307,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 20166
$metaTitle = 'LATEST NEWS UPDATES | EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal'
$metaKeywords = 'generic drugs,medicines,patents,Cancer,Health'
$metaDesc = '
-The Economic Times



MUMBAI: India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top...'
$disp = '<div align="justify">-The Economic Times</div><p align="justify"><br /><em>MUMBAI: </em>India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals.</p><p align="justify">A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006.</p><p align="justify">Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then.</p><p align="justify">Last year, the Canadian Supreme Court refused to grant patent to Pfizer's Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system.</p><p align="justify"> &quot;The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms&quot; said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada.</p><p align="justify"><br />Last year, Argentina amended its patent act to incorporate a law that said &quot;the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel&quot;. Other countries like Indonesia are also following suit taking a cue from Indian law. &quot;What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy,&quot; says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law.</p><p align="justify">&quot;I think that the decision could well embolden other countries to adopt India-style protections against ever greening,&quot; he added. India's Supreme Court on Monday declined to grant patent protection to Novartis' blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of &quot;evergreening&quot; or trivial innovations in an effort to get patent protection.</p><p align="justify">&quot;The decision by India's SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents,&quot; said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report.</p><p align="justify">She added that IP Australia's draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal

-The Economic Times MUMBAI: India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that an independent review should be set up to vet these proposals. A draft report on the possible changes was released by IP Australia, the government body. Canadian lawyers and health industry officials are discussing tighter standards and taking comfort from the Indian law and the Supreme Court ruling on Monday denying patent protection to Glivec of Novartis. India was one of the first few countries to introduce a specific clause such as Section 3(d) way back in 1995 when it passed the product patent legislation. This section forces the patent applicant to prove the medical or therapeutic efficacy of any incremental innovation for which it is seeking a patent. The law came into effect from 2005 and Novartis filed the case against the Indian government in 2006. Though the final decision on Novartis came only on Monday, the provisions of the Indian law was well known in international IP and pharma circles and countries and courts have been modifying their stance since then. Last year, the Canadian Supreme Court refused to grant patent to Pfizer's Viagra saying that the company has not proved the efficacy of the compound that it was seeking to patent. Last month, the European Union sounded an alarm last month over loose patent standards saying that there is widespread concern that patent quality is deteriorating and that the low patent quality threatens the functioning of the entire system. "The Indian ruling is not an isolated one; we are seeing in Canada, courts are under pressure to strengthen their patent standards. What we are seeing is that the developed world is taking a cue from developing countries in drafting patent norms" said Ikechi Mgbeoji, lawyer, and associate professor with Osgoode Hall Law School based out of Toronto, Canada. Last year, Argentina amended its patent act to incorporate a law that said "the discovery of a different or improved characteristic or property for a particular element or a group of elements already known in the prior art does not mean that the product or process is novel". Other countries like Indonesia are also following suit taking a cue from Indian law. "What the Novartis decision does is give other countries an imprimatur from a highly respected court that restricting ever greening is an important public policy," says Brooke Baker, professor of Law, Northeastern School of Law, who advised the Uganda government in drafting its patent law. "I think that the decision could well embolden other countries to adopt India-style protections against ever greening," he added. India's Supreme Court on Monday declined to grant patent protection to Novartis' blood-cancer busting drug Glivec. The denial created a world-wide stir and was widely welcomed by pharma NGOs, activists and aid organisations and by Indian government and domestic pharma companies. Novartis and other multinationals criticised the ruling saying that it is a setback to innovation and research. But the release of the Australian government report shows that Australia and health experts are also concerned about what they see as a widespread misuse of "evergreening" or trivial innovations in an effort to get patent protection. "The decision by India's SC is an important addition in our case as an example to the fact, that national courts and national laws can have more control over patents and limit patents," said Dr Patricia Ranald, convenor of Australian Fair Trade and Investment Network, a lobby group that advises government on trade and investment decisions. The organisation was one of the many which submitted recommendations to the report. She added that IP Australia's draft report is recommending that Australia not extend patents any further and that existing patent law be reviewed to make it more difficult to obtain patents on drugs that really do not add to the medical efficiency or effectiveness of the medicines.